Exagen (NASDAQ:XGN) operates as a molecular diagnostics company focused on the development, manufacture and commercialization of proprietary assays and testing solutions for autoimmune diseases. Its primary business activity involves the design and production of immunoassays and molecular tests that aid in the diagnosis and management of systemic autoimmune disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis and Sjögren’s syndrome. By leveraging chemiluminescent and fluorescent detection technologies, Exagen seeks to provide clinicians with accurate, reproducible tools to inform therapeutic decisions and monitor disease activity over time.
The company’s product portfolio is anchored by the Quanta Flash™ and Quanta Lite® lines of assays, which encompass a broad range of autoantibody panels targeting biomarkers such as anti–double-stranded DNA (dsDNA), anti–extractable nuclear antigens (ENA) and anti–cyclic citrullinated peptide (CCP) antibodies. Exagen also offers specialized testing kits for antiphospholipid syndrome and includes instrumentation compatible with common laboratory platforms to facilitate seamless integration into clinical lab workflows. In addition to in vitro diagnostic products, the company provides training, technical support and quality control materials designed to optimize assay performance across diverse laboratory settings.
Founded in 2003 and headquartered in Vista, California, Exagen has evolved through a combination of organic growth and strategic partnerships, extending its reach into North America, Europe and select Asia-Pacific markets. The company completed its initial public offering in 2015, enhancing its capacity to invest in research and development. In 2020, Exagen rebranded from its former name, ODX, to better reflect its focus on the intersection of autoimmunity and genomic science. Throughout its history, Exagen has prioritized collaborations with academic institutions and clinical research organizations to validate its assays and drive regulatory clearances.
Under the leadership of President and Chief Executive Officer Stuart R. Lichter, Exagen maintains a management team and board of directors with extensive experience in diagnostics, biotechnology and clinical laboratory operations. The company continues to invest in pipeline expansion efforts aimed at identifying novel biomarkers and improving multi-analyte test panels. By combining scientific innovation with a commitment to laboratory excellence, Exagen positions itself as a specialized partner for healthcare providers seeking advanced solutions in the diagnosis and monitoring of autoimmune disease.
